<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">RIFAMPIN <img border="0" src="../images/pr.gif"/></span><br/>(rif'am-pin)<br/><span class="topboxtradename">Rifadin, </span><span class="topboxtradename">Rimactane, </span><span class="topboxtradename">Rofact <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">antituberculosis agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>150 mg, 300 mg capsules; 600 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic derivative of rifamycin B, an antibiotic derived from <i>Streptococcus mediterranei,</i> with bacteriostatic and bactericidal actions. Inhibits DNA-dependent RNA polymerase activity in susceptible bacterial cells,
         thereby suppressing RNA synthesis.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Active against <i>Mycobacterium tuberculosis, M. leprae, Neisseria meningitidis,</i> and a wide range of gram-negative and gram-positive organisms. It is used in conjunction with other antitubercular agents
         to treat tuberculosis because resistant strains emerge rapidly when it is employed alone.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Primarily as adjuvant with other antituberculosis agents in initial treatment and retreatment of clinical tuberculosis; as
         short-term therapy to eliminate meningococci from nasopharynx of asymptomatic carriers of <i>N. meningitidis</i> when risk of meningococcal meningitis is high.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Chemoprophylaxis in contacts of patients with <i>Haemophilus influenzae</i> type B infection; alone or in combination with dapsone and other antiinfectives in treatment of leprosy (especially dapsone-resistant
         leprosy). Also infections caused by susceptible gram-negative and gram-positive bacteria that fail to respond to other antiinfectives;
         in combination with erythromycin or tetracycline for treatment of Legionnaire's disease.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to rifampin; obstructive biliary disease; meningococcal disease; intermittent rifampin therapy; lactation.
         Safe use during pregnancy (category C) or in children 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic disease; history of alcoholism; concomitant use of other hepatotoxic agents.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Pulmonary Tuberculosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 600 mg once/d in conjunction with other antituberculosis agents<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1020 mg/kg/d (max: 600 mg/d)<br/><br/><span class="indicationtitle">Meningococcal Carriers</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg b.i.d. for 2 consecutive d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1020 mg/kg b.i.d. for 2 consecutive d (max: 600 mg/d)<br/><br/><span class="indicationtitle">Prophylaxis for <i>H. influenzae</i> Type B</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg/d for 4 d<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 1020 mg/kg/d for 4 d (max: 600 mg/d)<br/><br/><span class="indicationtitle">Dapsone-Sensitive Multibacillary Leprosy</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 600 mg once/mo with clofazimine and dapsone for a minimum of 2 y<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give 1 h before or 2 h after a meal. Peak serum levels are delayed and may be slightly lower when given with food; capsule
            contents may be emptied into fluid or mixed with food.
         </li>
<li> 				Note: An oral suspension can be prepared from capsules for use with pediatric patients. Consult pharmacist for directions. 			</li>
<li>Keep a desiccant in bottle containing capsules to prevent moisture causing instability.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Dilute by adding 10 mL of sterile water for injection to each 600-mg vial to yield 60 mg/mL. Swirl to dissolve. Withdraw the
                  ordered dose and further dilute in 500 mL (preferred) of D5W. If necessary, 100 mL of D5W may be used.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Infuse 500 mL solution over 3 h and 100 mL solution over 30 min. Note: A less concentrated solution infused over a longer
                  period is preferred.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Minocycline.</b> <span class="incompattype">Y-site:</span> <b>Diltiazem.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Use diluted solution within 4 h of preparation.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Fatigue, drowsiness, headache, ataxia, confusion, dizziness, inability to concentrate, generalized numbness, pain in extremities,
      muscular weakness. <span class="typehead">Special Senses:</span> Visual disturbances, transient low-frequency hearing loss, conjunctivitis. <span class="typehead">GI:</span> <span class="speceff-common">Heartburn, epigastric distress, nausea, vomiting, anorexia, flatulence, cramps, diarrhea,</span> <span class="speceff-life">pseudomembranous colitis</span>, <span class="speceff-common">transient elevations in liver function tests</span> (bilirubin, BSP, alkaline phosphatase, ALT, AST), pancreatitis. <span class="typehead">Hematologic:</span> Thrombocytopenia, transient leukopenia, anemia, including hemolytic anemia. <span class="typehead">Body as a Whole:</span> Hypersensitivity (fever, pruritus, urticaria, skin eruptions, soreness of mouth and tongue, eosinophilia, hemolysis), flu-like
      syndrome. <span class="typehead">Urogenital:</span> Hemoglobinuria, hematuria, <span class="speceff-life">acute renal failure</span>, light-chain proteinuria, menstrual disorders, <span class="speceff-life">hepatorenal syndrome</span>, (with intermittent therapy). <span class="typehead">Respiratory:</span> Hemoptysis. <span class="typehead">Other:</span> Increasing lethargy, liver enlargement and tenderness, jaundice, brownish-red or orange discoloration of skin, sweat, saliva,
      tears, and feces; unconsciousness. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Rifampin interferes with contrast media used for <span class="alt">gallbladder study;</span> therefore, test should precede daily dose of rifampin. May also cause retention of <span class="alt">BSP.</span> Inhibits standard assays for <span class="alt">serum folate</span> and <span class="alt">vitamin B<sub>12</sub>.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> <b>Alcohol,</b> <b>isoniazid,</b> <b>pyrazinamide</b>, <b>ritonavir,</b> saquinavir increase risk of drug-induced hepatotoxicity (including fatal hepatotoxicity when used for latent TB); <b> <i>p</i>-aminosalicylic acid (PAS)</b> decreases concentrations of rifampin; decreases concentrations of <b>alfentanil,</b> <b>alosetron,</b> <b>alprazolam,</b> <b>amprenavir,</b> <span class="classification">barbiturates</span>, <span class="classification">benzodiazepines</span>, <b>carbamazepine,</b> <b>atovaquone,</b> <b>cevimeline,</b> <b>chloramphenicol,</b> <b>clofibrate,</b> <span class="classification">corticosteroids</span>, <b>cyclosporine,</b> <b>dapsone,</b> <b>delavirdine,</b> <b>diazepam,</b> <b>digoxin,</b> <b>diltiazem,</b> <b>disopyramide,</b> <b>estazolam,</b> <b>estramustine,</b> <b>fentanyl,</b> <b>fosphenytoin,</b> <b>fluconazole galantamine,</b> <b>indinavir,</b> <b>itraconazole,</b> <b>ketoconazole,</b> <b>lamotrigine,</b> <b>levobupivacaine,</b> <b>lopinavir,</b> <b>methadone,</b> <b>metoprolol,</b> <b>mexiletine,</b> <b>midazolam,</b> <b>nelfinavir,</b> <span class="classification">oral sulfonylureas</span>, <span class="classification">oral contraceptives</span>, <b>phenytoin,</b> <span class="classification">progestins</span>, <b>propafenone,</b> <b>propranolol,</b> <b>quinidine,</b> <b>quinine,</b> <b>ritonavir,</b> <b>sirolimus,</b> <b>theophylline,</b> <span class="classification">thyroid hormones</span>, <b>tocainide,</b> <b>tramadol,</b> <b>verapamil,</b> <b>warfarin,</b> <b>zaleplon,</b> and <b>zonisamide,</b> leading to potential therapeutic failure. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 24 h. <span class="typehead">Distribution:</span> Widely distributed, including CSF; crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> Metabolized in liver to active and inactive metabolites; is enterohepatically cycled. <span class="typehead">Elimination:</span> Up to 30% excreted in urine, 6065% in feces. <span class="typehead">Half-Life:</span> 3 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Periodic liver function tests are advised. Closely monitor patients with hepatic disease.</li>
<li>Check prothrombin time daily or as necessary to establish and maintain required anticoagulant activity when patient is also
            receiving an anticoagulant.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not interrupt prescribed dosage regimen. Hepatorenal reaction with flu-like syndrome has occurred when therapy has been
            resumed following interruption.
         </li>
<li>Be aware that drug may impart a harmless red-orange color to urine, feces, sputum, sweat, and tears. Soft contact lenses may
            be permanently stained.
         </li>
<li>Report onset of jaundice, hypersensitivity reactions, and persistence of GI adverse effects to physician.</li>
<li>Use or add barrier contraceptive if using hormonal contraception. Concomitant use of rifampin and oral contraceptives leads
            to decreased effectiveness of the contraceptive and to menstrual disturbances (spotting, breakthrough bleeding).
         </li>
<li>Keep drug out of reach of children.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>